Cargando…
Erratum in: SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
The Association for Research in Vision and Ophthalmology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587469/ https://www.ncbi.nlm.nih.gov/pubmed/36259679 http://dx.doi.org/10.1167/tvst.11.10.31 |
Ejemplares similares
-
SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy
por: Nguyen, Huy, et al.
Publicado: (2022) -
Erratum in: Hydrogen Sulfide: A Potential Therapeutic Target in the Development of Diabetic Retinopathy
Publicado: (2021) -
Erratum to “Epigenetic Modifications and Potential New Treatment Targets in Diabetic Retinopathy”
por: Perrone, Lorena, et al.
Publicado: (2014) -
Erratum to “The rapid and sustained responses of dendritic cells to influenza virus infection in a non-human primate model” [Braz. J. Infect. Dis. 18(4) (2014) 406–413]
por: Jie, Zhijun, et al.
Publicado: (2014) -
Self-Reported Awareness of Retinopathy Severity in Diabetic Patients [Erratum]
Publicado: (2020)